reports
Floridienne S.A.: 1 director
A director at Floridienne S.A. bought 60 shares at 615.000EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Luis de Toledo Heras
ITP INTERPARFUMS
RWE RWE AG
AALB AALBERTS N.V.
SEFER SERGEFERRARI GROUP SA
SSO SCATEC ASA
ENG ENAGAS SA
DGM DIAGNOSTIC MEDICAL SYSTEMS
GLPG GALAPAGOS NV
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
COPN COSMO PHARMACEUTICALS NV
HOME NEINOR HOMES SA
GRE GRENERGY RENOVABLES
DSC1 DUTCH STAR C SHAR
OVH OVH GROUPE
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
PLNW PLANISWARE
ATO ATOS SE
- Luis de Toledo Heras
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ITP INTERPARFUMS
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
RWE RWE AG
01913 PRADA S.P.A.
AALB AALBERTS N.V.
MONC MONCLER SPA
SEFER SERGEFERRARI GROUP SA
SSO SCATEC ASA
ENG ENAGAS SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
DGM DIAGNOSTIC MEDICAL SYSTEMS
GLPG GALAPAGOS NV
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
COPN COSMO PHARMACEUTICALS NV
HOME NEINOR HOMES SA
GRE GRENERGY RENOVABLES
DSC1 DUTCH STAR C SHAR
OVH OVH GROUPE
ALLFG ALLFUNDS (UK) LTD
ZGN ERMENEGILDO ZEGNA NV
FLOW FLOW TRADERS LTD
PLNW PLANISWARE
ATO ATOS SE
- Martial Descoutures
- Martial Descoutures
- Jacob Mekhael
Autolus Doses first patient in phase 1 trial of Aucatzyl in progressiv...
Yesterday, before US market opens, Autolus announced that the first patient has been dosed in the phase 1 (BOBCAT, NCT07139743) trial of Aucatzyl (obe-cel, CD19 CAR-T) in patients with progressive multiple sclerosis (PMS). This comes in line with the company's previously guided timeline to initiate the trial by YE25. While relapsing MS has multiple treatment options, there remains a need to address the progressive form of the disease, which is characterised by CNS-compartmentalised inflammation....
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
- Jacob Mekhael
Galapagos Intends to wind down cell therapy business
Galapagos announced its intention to wind down its cell therapy business following a strategic review. This follows a previous announcement of non-binding offers, subject to financing, where previous CEO Paul Stoffels emerged as one of the bidders for the business. This decision suggests external financing for the project has not been obtained, and we believe the decision to wind down the cell therapy business creates clarity and allows Galapagos to move forward with its new plans of building a ...
- Guy Sips
Floridienne Monoholding in Disguise
Floridienne is a holding with full private market exposure, ESG focus, and long-term family stewardship. Floridienne transformed over the past decade from a multi-asset to a de facto mono-holding. The main driver of this transformation is the superior performance of its crown jewel BioFirst, a global leader in biocontrol benefiting from the trend toward sustainability in agriculture. Floridienne's valuation and investment thesis depend on its continued success story. We reiterate our Accumulate ...
Galapagos Announces Intention to Wind Down Cell Therapy Business as Pa...
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its intention to wind down its cell therapy business and pursue new transformational business development transactions with its available cash resources. The in...
Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen...
Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen als onderdeel van de voortdurende transformatie van het bedrijf Deze intentie volgt na een uitgebreid strategisch evaluatieproces en zou de meest optimale manier zijn om kapitaal toe te wijzen ter ondersteuning van een sterkere en duurzame toekomst voor Galapagos Mechelen, België; 21 oktober 2025, 07:30 CET; gereglementeerde informatie – voorwetenschap – Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag de intentie aan om haar celtherapieactiviteiten af te bouwen en met zijn beschikbare kasmiddelen nieuwe baanbre...
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of...
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis LONDON and Gaithersburg, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the first patient has been dosed in its Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) in patients with progressive multiple sclerosis (PMS). The patient was treated at Univ...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Thibault Leneeuw
- Wim Lewi
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
Galapagos Announces Appointment of Fred Blakeslee as General Counsel Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period. “We are very pleased to welcome Fred to the executive team,” said Henry Gosebruch, CEO of Galapagos. “He brings a unique combination of top-tier legal expertise, global business transaction experience, an...
Galapagos kondigt benoeming aan van Fred Blakeslee als General Counsel
Galapagos kondigt benoeming aan van Fred Blakeslee als General Counsel Mechelen, België; 16 oktober 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag de benoeming bekendgemaakt van de heer Fred Blakeslee tot Executive Vice President en General Counsel met ingang van 16 oktober 2025. Blakeslee volgt mevrouw Valeria Cnossen op, die het bedrijf zal verlaten na een korte transitieperiode. “We zijn erg blij Fred te mogen verwelkomen in het managementteam,” aldus Henry Gosebruch, CEO van Galapagos. “Hij combineert juridische expertise op topniveau met ruime ervaring in inter...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing ...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON and GAITHERSBURG, Md., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 1,093,300 shares of its common stock to 65 employees pursuant to the Company’s 2025 Inducement Plan. The stock ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Wim Lewi
- Jacob Mekhael
Galapagos Media reports Paul Stoffels behind non-binding offer for cel...
According to media reports, Paul Stoffels, Galapagos' previous CEO, has assembled a group of investors to bid for the company's cell therapy business. After joining Galapagos in 2022, Paul Stoffels pivoted the company towards cell therapies and focussed the company's efforts on de-centralised CAR-T manufacturing as a way to broaden access to such treatments. Following his resignation earlier this year, he now has placed a non-binding offer for the cell therapy business which is under strategic r...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
Galapagos Receives non-binding offers for cell therapy business
Galapagos announced that it has received a limited number of non-binding offers from consortia, predominantly comprised of financial investors, to acquire the cell therapy business. The deadline for potential bidders to put forward binding, fully-financed, offers is in the coming weeks. The company will make an announcement on the outcome of the review of strategic alternatives for the cell therapy business no later than its 3Q25 update on 5 November 2025. € 37 TP and ACCUMULATE reiterated.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.